MedTrace Logo

Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination

NCT02897232 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 386

Last updated 2021-02-10

No results posted yet for this study

Summary

This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding Human Papillomavirus (HPV) infection, associated diseases and to identify barriers which prevent these groups from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection.

The research is focused on these questions:

Do community members understand the ease of transmission of the HPV virus in males 9-26? Do community members, physicians, residents and medical students have knowledge of the associated diseases that may occur with the HPV virus infection in males age 9-26? Do community members, physicians, residents and medical students know the ages in which males should receive the HPV vaccine three-shot series? What barriers prevent community members and physicians, residents and medical students from ensuring that males 9-26 receive the three-shot vaccine series to prevent HPV infection?

Conditions

  • Papillomavirus Infections
  • Health Behavior
  • Attitude of Health Personnel
  • Human Papilloma Virus, Male

Interventions

OTHER

Survey

Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination

Sponsors & Collaborators

  • Louisiana State University Health Sciences Center Shreveport

    lead OTHER

Principal Investigators

  • Julia M Esparza, MLS · 3186754179

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-03-31
Completion
2020-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02897232 on ClinicalTrials.gov